Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award

Rhea-AI Filing Summary

Gaskins Tammi L reported acquisition or exercise transactions in this Form 4 filing.

IRONWOOD PHARMACEUTICALS INC reported that Chief Commercial Officer Tammi L. Gaskins received an equity grant of 136,612 shares of Class A Common Stock in the form of restricted stock units. These units were granted at no cash cost and represent a compensation award rather than an open-market purchase.

The award, described as an annual performance grant, vests in four equal installments of 25% on each approximate anniversary of the grant date, tying value to continued service and performance over time. Following this grant, Gaskins’ direct holdings increased to 350,350 shares of Class A Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gaskins Tammi L

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	136,612	$0.00	--

Holdings After Transaction: Class A Common Stock — 350,350 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gaskins Tammi L

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/10/2026		A(1)		136,612	A	$0	350,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.

	/s/ Amir Vitale, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRWD report for Tammi L. Gaskins on this Form 4?

IRONWOOD PHARMACEUTICALS reported that Chief Commercial Officer Tammi L. Gaskins received 136,612 shares of Class A Common Stock as a restricted stock unit grant. The award is compensation-based, not an open-market purchase, and was reported at a price of $0.00 per share.

How many IRWD shares does Tammi L. Gaskins hold after the reported grant?

After the grant, Tammi L. Gaskins holds 350,350 shares of IRONWOOD’s Class A Common Stock directly. This total includes the newly awarded 136,612 restricted stock units reported in the Form 4 insider filing as part of her equity compensation.

What are the vesting terms of Tammi L. Gaskins’ new IRWD restricted stock unit award?

The restricted stock unit award for 136,612 shares vests in four equal installments of 25% each. Vesting occurs on each approximate anniversary of the grant date, reflecting an annual performance award structure tied to ongoing employment and service.

Was cash paid for the 136,612 IRWD shares reported for Tammi L. Gaskins?

No cash was paid for these 136,612 shares, which were granted at a reported price of $0.00 per share. They represent a restricted stock unit compensation award to the Chief Commercial Officer rather than an open-market stock purchase transaction.

Is Tammi L. Gaskins’ IRWD equity award a direct or indirect holding?

The Form 4 shows the 136,612-share restricted stock unit award as a direct holding of Tammi L. Gaskins. The ownership code is listed as “D” for direct, with no indication of trusts or other indirect ownership entities in this transaction.